학술논문
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Document Type
article
Author
Britton Boras; Rhys M. Jones; Brandon J. Anson; Dan Arenson; Lisa Aschenbrenner; Malina A. Bakowski; Nathan Beutler; Joseph Binder; Emily Chen; Heather Eng; Holly Hammond; Jennifer Hammond; Robert E. Haupt; Robert Hoffman; Eugene P. Kadar; Rob Kania; Emi Kimoto; Melanie G. Kirkpatrick; Lorraine Lanyon; Emma K. Lendy; Jonathan R. Lillis; James Logue; Suman A. Luthra; Chunlong Ma; Stephen W. Mason; Marisa E. McGrath; Stephen Noell; R. Scott Obach; Matthew N. O’ Brien; Rebecca O’Connor; Kevin Ogilvie; Dafydd Owen; Martin Pettersson; Matthew R. Reese; Thomas F. Rogers; Romel Rosales; Michelle I. Rossulek; Jean G. Sathish; Norimitsu Shirai; Claire Steppan; Martyn Ticehurst; Lawrence W. Updyke; Stuart Weston; Yuao Zhu; Kris M. White; Adolfo García-Sastre; Jun Wang; Arnab K. Chatterjee; Andrew D. Mesecar; Matthew B. Frieman; Annaliesa S. Anderson; Charlotte Allerton
Source
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
The 3CL protease of SARS-CoV-2 is inhibited by PF-00835231 in vitro. Here, the authors show that the prodrug PF-07304814 has broad spectrum activity, inhibiting SARS-CoV and SARS-CoV-2 in mice and its ADME and safety profile support clinical development.